Neuromuscular Blocking Agents in ARDS
Author:
- Arthur S. SlutskyASArthur S. Slutsky
- 16 September 2010
- journal article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 363 (12) , 1176-1180
Abstract
In this issue of the Journal, Papazian and colleagues1 present intriguing results of their study examining neuromuscular blockade in patients with severe, early acute respiratory distress syndrome (ARDS). The investigators randomly assigned 340 patients to receive the neuromuscular blocking agent cisatracurium or placebo for a period of 48 hours. Both groups underwent mechanical ventilation according to a lung-protective strategy previously shown to decrease mortality.2 Both the adjusted 90-day survival rate and time off the ventilator were greater in the cisatracurium group as compared with the placebo group.ARDS is an inflammatory disease characterized by pulmonary edema, stiff lungs, and hypoxemia. . . .Keywords
This publication has 15 references indexed in Scilit:
- Neuromuscular Blockers in Early Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2010
- Clinical trials of early mobilization of critically ill patientsCritical Care Medicine, 2009
- A New Era for Sedation in ICU PatientsJAMA, 2009
- Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress SyndromeCurrent Medicinal Chemistry, 2008
- Noninvasive ventilation in acute respiratory failureCritical Care Medicine, 2007
- Incidence and Outcomes of Acute Lung InjuryNew England Journal of Medicine, 2005
- Causes and Timing of Death in Patients With ARDSChest, 2005
- The Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000
- Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress SyndromeNew England Journal of Medicine, 2000
- A Multicenter, Randomized, Controlled Clinical Trial of Transfusion Requirements in Critical CareNew England Journal of Medicine, 1999